You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for ASTX660


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug ASTX660?

ASTX660 is an investigational drug.

There have been 8 clinical trials for ASTX660. The most recent clinical trial was a Phase 1 trial, which was initiated on July 14th 2020.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, T-Cell, Peripheral, and Lymphoma, T-Cell. The leading clinical trial sponsors are Astex Pharmaceuticals, Inc., Astex Pharmaceuticals, and Otsuka Pharmaceutical Co., Ltd.

There are two US patents protecting this investigational drug and forty-four international patents.

Recent Clinical Trials for ASTX660
TitleSponsorPhase
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)Astex Pharmaceuticals, Inc.Phase 1/Phase 2
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck CancerAstex Pharmaceuticals, Inc.Early Phase 1
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck CancerEmory UniversityEarly Phase 1

See all ASTX660 clinical trials

Clinical Trial Summary for ASTX660

Top disease conditions for ASTX660
trials0112233LymphomaLymphoma, T-Cell, PeripheralLymphoma, T-CellLeukemia[disabled in preview]
Top clinical trial sponsors for ASTX660
trials01234567Astex Pharmaceuticals, Inc.Astex PharmaceuticalsOtsuka Pharmaceutical Co., Ltd.[disabled in preview]

See all ASTX660 clinical trials

US Patents for ASTX660

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
ASTX660 ⤷  Subscribe Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LIMITED (Cambridge, GB) ⤷  Subscribe
ASTX660 ⤷  Subscribe Bicyclic heterocycle compounds and their uses in therapy ASTEX THERAPEUTICS LIMITED (Cambridge, GB) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 2 of 2 entries

International Patents for ASTX660

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
ASTX660 Argentina AR098838 2033-12-20 ⤷  Subscribe
ASTX660 Australia AU2014369446 2033-12-20 ⤷  Subscribe
ASTX660 Australia AU2019200840 2033-12-20 ⤷  Subscribe
ASTX660 Brazil BR112016014561 2033-12-20 ⤷  Subscribe
ASTX660 Canada CA2933939 2033-12-20 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 5 of 5 entries

Development Update and Market Projection for ASTX660

Introduction to ASTX660

ASTX660, also known as tolinapant, is a novel, orally administered, non-peptidomimetic small-molecule antagonist of cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Developed by Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical Co., Ltd., this drug candidate is being investigated for its potential in treating advanced solid tumors and lymphomas.

Mechanism of Action

ASTX660 works by inhibiting the activity of cIAP1/2 and XIAP, proteins that are often overexpressed in cancer cells and contribute to tumor growth, progression, and resistance to treatment. By blocking these proteins, ASTX660 promotes apoptosis (cell death) in cancer cells, which is a critical mechanism in cancer therapy[1][3].

Clinical Trials and Development

Phase I Study

The first-in-human phase I study of ASTX660 evaluated its safety, pharmacokinetics, and preliminary clinical activity in patients with advanced solid tumors or lymphoma. The study used a 7-day-on/7-day-off dosing schedule in a 28-day cycle. The recommended phase II dose (RP2D) was determined to be 180 mg/day, at which ASTX660 demonstrated a manageable safety profile and evidence of pharmacodynamic and clinical activity. Notably, ASTX660 suppressed cIAP1 in peripheral blood mononuclear cells, and clinical activity was observed in a patient with cutaneous T-cell lymphoma[1].

Ongoing and Future Studies

The phase II part of the study is currently enrolling patients. Additionally, ASTX660 is being investigated in combination with standard of care FOLFOX chemotherapy in metastatic colorectal cancer in a separate phase I study[3].

Regulatory Status

ASTX660 has been granted orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of T-cell lymphoma, including peripheral T-cell lymphoma and cutaneous T-cell lymphoma. This designation provides seven years of marketing exclusivity in the US following product approval, along with certain tax incentives and grants[5].

Market Projection

Peripheral T-Cell Lymphoma Market

The peripheral T-cell lymphoma market is expected to grow significantly, driven by the launch of new therapies and a robust clinical pipeline. According to DelveInsight, the market size for peripheral T-cell lymphoma was approximately USD 564 million in 2021 in the 7MM (the United States, EU-4, the United Kingdom, and Japan) and is anticipated to grow at a CAGR of 4.9% by 2032. The total incident population of PTCL in the 7MM was around 18,000 in 2022 and is expected to increase during the study period[2].

Competitive Landscape

The market for peripheral T-cell lymphoma is competitive, with several companies developing novel therapies. Key players include Viracta Therapeutics, Dizal Pharmaceuticals, CStone Pharmaceuticals, and others. The emergence of new treatments, such as ADCETRIS, Azacitidine (CC-486), and COPIKTRA (Duvelisib), is expected to further drive market growth[2].

Clinical Significance and Unmet Need

T-cell lymphoma, particularly peripheral T-cell lymphoma, remains a challenging disease area with a poor prognosis and high unmet medical need. The current treatments often have limited efficacy, and there is a significant need for new therapeutic options. ASTX660, with its unique mechanism of action and promising early clinical data, represents a potential new therapeutic option for these patients[5].

Safety and Tolerability

ASTX660 has demonstrated a manageable safety profile in clinical trials. The phase I study showed that the drug was well tolerated, with no evidence of excessive weight loss or significant adverse effects at the recommended phase II dose[1].

Pharmacokinetics and Pharmacodynamics

Preclinical studies have shown that ASTX660 is orally bioavailable and distributes into tumor xenografts, with detectable levels maintained in these tumors for up to 7 days after a single oral dose. In the phase I study, ASTX660 suppressed cIAP1 in peripheral blood mononuclear cells, indicating sustained biologic activity[1].

Conclusion

ASTX660 is a promising drug candidate in the treatment of advanced solid tumors and lymphomas, particularly T-cell lymphomas. With its orphan drug designation and ongoing clinical trials, ASTX660 is poised to address a significant unmet medical need in this challenging disease area. The market projection indicates a growing demand for effective treatments in peripheral T-cell lymphoma, and ASTX660 could play a crucial role in meeting this demand.

Key Takeaways

  • Mechanism of Action: ASTX660 inhibits cIAP1/2 and XIAP, promoting apoptosis in cancer cells.
  • Clinical Trials: Phase I study completed; phase II study ongoing.
  • Regulatory Status: Granted orphan drug designation by the FDA for T-cell lymphoma.
  • Market Projection: Peripheral T-cell lymphoma market expected to grow at a CAGR of 4.9% by 2032.
  • Safety and Tolerability: Manageable safety profile with no significant adverse effects.
  • Pharmacokinetics and Pharmacodynamics: Orally bioavailable with sustained biologic activity.

FAQs

Q1: What is the primary mechanism of action of ASTX660? ASTX660 works by inhibiting the activity of cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP), promoting apoptosis in cancer cells.

Q2: What is the current clinical status of ASTX660? ASTX660 has completed its phase I study and is currently in the phase II part of the clinical trial.

Q3: What regulatory designation has ASTX660 received? ASTX660 has been granted orphan drug designation by the US FDA for the treatment of T-cell lymphoma.

Q4: How is the market for peripheral T-cell lymphoma expected to grow? The market is expected to grow at a CAGR of 4.9% by 2032, driven by new therapies and a robust clinical pipeline.

Q5: What are the key companies involved in the development of treatments for peripheral T-cell lymphoma? Key companies include Viracta Therapeutics, Dizal Pharmaceuticals, CStone Pharmaceuticals, and others, along with Astex Pharmaceuticals for ASTX660.

Sources

  1. A Phase I Study of ASTX660, an Antagonist of Inhibitors of Apoptosis ... - Clinical Cancer Research.
  2. Peripheral T-Cell Lymphoma Market to Observe Growth at a CAGR of 4.9% in the US by 2032 | DelveInsight - GlobeNewswire.
  3. Tolinapant - Drug Targets, Indications, Patents - Patsnap Synapse - Synapse.
  4. P53 tumour suppressor protein (Oncology) - Astex Pharmaceuticals - Astex Pharmaceuticals.
  5. Astex Pharmaceuticals Announces That Tolinapant (ASTX660), a ... - Astex Pharmaceuticals.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.